Medical Developments International Management
Management criteria checks 2/4
Medical Developments International's CEO is Brent MacGregor, appointed in Nov 2020, has a tenure of 5.17 years. total yearly compensation is A$1.26M, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth $138.61K. The average tenure of the management team and the board of directors is 5.3 years and 2.3 years respectively.
Key information
Brent MacGregor
Chief executive officer
AU$1.3m
Total compensation
| CEO salary percentage | 49.07% |
| CEO tenure | 5.2yrs |
| CEO ownership | 0.4% |
| Management average tenure | 5.3yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | AU$1m | AU$620k | AU$94k |
| Mar 31 2025 | n/a | n/a | -AU$15m |
| Dec 31 2024 | n/a | n/a | -AU$30m |
| Sep 30 2024 | n/a | n/a | -AU$35m |
| Jun 30 2024 | AU$6m | AU$602k | -AU$41m |
| Mar 31 2024 | n/a | n/a | -AU$30m |
| Dec 31 2023 | n/a | n/a | -AU$19m |
| Sep 30 2023 | n/a | n/a | -AU$12m |
| Jun 30 2023 | AU$2m | AU$576k | -AU$6m |
| Mar 31 2023 | n/a | n/a | -AU$4m |
| Dec 31 2022 | n/a | n/a | -AU$2m |
| Sep 30 2022 | n/a | n/a | -AU$7m |
| Jun 30 2022 | AU$2m | AU$547k | -AU$12m |
| Mar 31 2022 | n/a | n/a | -AU$16m |
| Dec 31 2021 | n/a | n/a | -AU$19m |
| Sep 30 2021 | n/a | n/a | -AU$16m |
| Jun 30 2021 | AU$1m | AU$351k | -AU$13m |
Compensation vs Market: Brent's total compensation ($USD871.27K) is above average for companies of similar size in the US market ($USD572.21K).
Compensation vs Earnings: Brent's compensation has been consistent with company performance over the past year.
CEO
Brent MacGregor (61 yo)
Mr. Brent MacGregor serves as an Independent Director at Dynavax Technologies Corporation since July 2020. He serves as an Independent Non-Executive Director since November 2025 at Vaxxas Pty. Ltd.He has...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 5.2yrs | AU$1.26m | 0.36% $ 138.6k | |
| Chief Financial Officer | 3.7yrs | AU$646.80k | 0.17% $ 67.5k | |
| Head of Operations & Supply Chain | no data | no data | no data | |
| Chief Scientific Officer | 6.5yrs | no data | no data | |
| General Counsel & Company Secretary | 3.4yrs | no data | no data | |
| Head of People & Culture | no data | no data | no data | |
| Head of Production | 5.5yrs | no data | no data | |
| Head of Europe | 5.4yrs | no data | no data | |
| Head of Medical Affairs & Clinical Development | no data | no data | no data | |
| Global Head of Respiratory | no data | no data | no data | |
| Head of Quality & Regulatory Affairs | no data | no data | no data | |
| Acting Head of Medical Affairs & Clinical Development | no data | no data | no data |
Experienced Management: MDDV.F's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chair of the Board | less than a year | AU$15.00k | 0.056% $ 21.7k | |
| Non-Executive Director | 2.3yrs | AU$60.00k | 0.050% $ 19.3k | |
| Deputy Chair | less than a year | AU$5.00k | 0.022% $ 8.6k | |
| Non-Executive Director | 12.3yrs | AU$60.00k | 0.063% $ 24.3k | |
| Non-Executive Director | 5.7yrs | AU$60.00k | 0.080% $ 31.2k |
Experienced Board: MDDV.F's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/25 05:48 |
| End of Day Share Price | 2026/01/09 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medical Developments International Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martyn Jacobs | Bell Potter |
| Martyn Jacobs | Canaccord Genuity |
| Dan Hurren | MST Financial Services Pty Limited |